Logical. I too am tempering expectations. Admittedly, I was anticipating a slew of announcements Q4 CY24 into Q1 CY25 with dosing early in the quarter sparking a re-rate leading into first dose. As frustrating as it is, waiting on paperwork, I still expect a different sentiment in 12-18 month time, assuming the trail from ethics approval goes as planned. Some big announcements coming tomorrow, next week, next mon-- I jest, but we know some stuff from RAC is cooking away.
Good luck all, we've been told "Bellberry is very fast in turning things around if they have any questions. The same applies to the lead site - they are a commercial site and they can move through the governance process much faster than the large public hospitals." We'll kick off soon, with the world's first MOPACS drug with multi-billion dollar market - we're in at the right time IMO, over to you RAC.
RAC Price at posting:
$1.24 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)